How much does the generic version of Encidipine cost?

Enasidenib is an oral targeted inhibitor used to treat patients with a specific type of hematological tumor, namely refractory or relapsed acute myeloid leukemia (AML). Its mechanism of action is mainly to exert anti-tumor effects by inhibiting the activity of IDH2 (isocitrate dehydrogenase 2) mutant.

Since ensidipine has not yet been marketed in China, patients are currently unable to purchase this drug directly in China. To meet their treatment needs, patients need to purchase them through overseas channels. In foreign markets, relatively affordable generic ensidipine drugs have become a viable option, especially the versions from Laos and Bangladesh, which are priced in the range of 2,000 to 4,000 yuan. The ingredients of these generic drugs are basically the same as those of the original drugs.

About 10% to 15% of patients with AML have IDH2 mutation, which leads to abnormal function of isocitrate dehydrogenase (IDH), thereby promoting the proliferation and survival of leukemia cells. Ensidipine inhibits the activity of IDH2 mutants and interferes with abnormal metabolic pathways, thereby inhibiting the growth and spread of leukemia cells, promoting cell differentiation, and ultimately leading to leukemia cell apoptosis.

Ensidipine is mainly suitable for refractory or relapsedAML patients who have experienced traditional chemotherapy regimens but failed to obtain durable remission or had poor tolerance. It is usually taken as an oral medication once daily. Before using ensidipine, a detailed clinical evaluation of the patient is required to ensure the presence of IDH2 mutations.

Clinical trials have shown that ensidipine has demonstrated significant anti-tumor activity in patients with refractory or relapsed AML and has produced durable clinical responses in some patients. However, ensidipine may also cause some adverse reactions, such as jaundice, nausea, vomiting, fatigue, etc. Therefore, the patient's condition needs to be closely monitored during use and appropriate treatment measures must be taken.

In summary, ensidipine is an oral inhibitor targeting IDH2 mutations for the treatment of patients with refractory or relapsed AML. It provides a new treatment option for these patients and brings hope for improving patients' survival and quality of life.